Full-Time

ML Engineer

Posted on 7/3/2025

Deadline 7/9/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$86.1k - $124.4k/yr

Mid

Toronto, ON, Canada

Hybrid

Category
Applied Machine Learning
AI & Machine Learning
Required Skills
Kubernetes
Microsoft Azure
Python
Git
Machine Learning
Postgres
Docker
Tableau
AWS
Terraform
Snowflake
Google Cloud Platform
Requirements
  • University degree (Bachelor, Master or PhD) in Computer Science, Information Systems, Software Engineering, or another quantitative field.
  • Minimum 2 years of experience in building, deploying, monitoring and maintaining AI/ML applications utilizing cloud technologies (e.g., AWS, GCP, Azure, Snowflake etc.).
  • Ability to work across the full stack and move fluidly between programming languages (e.g., Python) and MLOps technologies (e.g.Github, Argo, Metaflow, WandB, Snowflake, AWS SageMaker)
  • Experience in implementing CI/CD pipelines for AI/ML driven app development
  • Experience in building and deploying apps with large scale data and ML pipelines
  • Ability to assess new technologies and compile architecture decision records (ADRs)
  • Experience working in an agile team supporting and working with cross-functional teams
  • Knowledge of relational (e.g., Postgres SQL) and non-relational databases (e.g., Graph database, Vector Database etc.)
  • Experience in visualization technologies (e.g. Python DASH, Tableau, PowerBI)
  • Experience in developing and maintaining backend APIs (e.g. REST)
  • Experience in provisioning cloud infrastructure leveraging Infrastructure as a code tools (e.g.: Docker, Kubernetes, Terraform)
  • Experience in cloud-based ML engineering in an industrial setting within a global organization (technology company preferred)
  • Experience in working within compliance (e.g. quality, regulatory - data privacy, GxP, SOX) and knowledge in cybersecurity is a plus
Responsibilities
  • Work in an agile development pod to design, build and maintain cloud hosted AI/ML products with automated pipelines that run, monitor, and retrain ML Models
  • Implement automated ML pipelines (e.g., training and inference) working closely with other peers e.g., data scientists and data engineers
  • Support life cycle management of deployed AI/ML apps (e.g., new releases, change management, monitoring and troubleshooting)
  • Work as subject matter expert in MLOps (e.g., develop and maintain enterprise standards, user guides, release notes, FAQs)
  • Build processes and reusable components supporting seamless ML Operations (e.g., app monitoring, troubleshooting, life cycle management and customer support)
  • Walk stakeholders and solution partners through solutions and reviewing product change and development needs
  • Maintain effective relationships with app userbase to develop education and communication content as per life cycle events
  • Research and gain expertise on emerging tools and technologies. An enthusiasm to ask questions and try and learn new things is essential
Desired Qualifications
  • Experience in working within compliance (e.g. quality, regulatory - data privacy, GxP, SOX) and knowledge in cybersecurity is a plus

Sanofi provides healthcare solutions through its focus on pharmaceuticals and biotechnology. The company develops treatments and vaccines aimed at addressing medical needs in areas like immunology, oncology, and rare diseases. Sanofi's products work by utilizing advanced research and development to create effective therapies and vaccines that improve health outcomes. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and a diverse portfolio that includes prescription medicines and over-the-counter products. The company aims to enhance the quality of life for people globally by ensuring access to its life-saving products and maintaining a commitment to quality and safety.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Blueprint Medicines expands its portfolio in rare immunological diseases.
  • The approval of Dupixent for chronic spontaneous urticaria opens new market opportunities.
  • Sanofi's investment in Adagene supports innovative cancer treatment development.

What critics are saying

  • Large-scale acquisitions may strain Sanofi's financial stability if returns are insufficient.
  • Regulatory challenges could delay the market entry of new treatments like tolebrutinib.
  • Dependence on strategic partnerships may pose risks if collaborations don't meet expectations.

What makes Sanofi unique

  • Sanofi's extensive R&D efforts focus on unmet medical needs in immunology and oncology.
  • The company leverages strategic partnerships to enhance its product pipeline and market reach.
  • Sanofi's global presence allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Investors Hangout
Jul 1st, 2025
Adagene Secures $25M Investment from Sanofi

Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to advance its research and development, particularly for the clinical trials of muzastotug (ADG126), an anti-CTLA-4 SAFEbody targeting microsatellite stable colorectal cancer. This funding will extend Adagene's operational runway into 2027 and includes a phase 2 trial with over 100 patients. The partnership also allows Sanofi a role in Adagene's Scientific Advisory Board.

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

INACTIVE